Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Company Overview

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $0.45 to $0.48
• 50-Day Range: $0.45 to $0.84
• 52-Week Range: $0.43 to $3.10
• Volume: 14,002 shs
• Average Volume: 142,194 shs
• Market Capitalization: $7.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Indaptus Therapeutics Stock Analysis - MarketRank™

Indaptus Therapeutics scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Indaptus Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indaptus Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indaptus Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Indaptus Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.02% of the float of Indaptus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indaptus Therapeutics has recently decreased by 40.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indaptus Therapeutics does not currently pay a dividend.

Dividend Growth

Indaptus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.02% of the float of Indaptus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indaptus Therapeutics has recently decreased by 40.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.44

News Sentiment

Indaptus Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Indaptus Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.50% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.06% of the stock of Indaptus Therapeutics is held by institutions.

INDP Stock Analysis - Frequently Asked Questions

How have INDP shares performed this year?

Indaptus Therapeutics' stock was trading at $0.8421 at the beginning of 2025. Since then, INDP shares have decreased by 44.2% and is now trading at $0.47.
View the best growth stocks for 2025 here.

How were Indaptus Therapeutics' earnings last quarter?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) released its quarterly earnings results on Thursday, March, 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.03.

How do I buy shares of Indaptus Therapeutics?

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Indaptus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 5/02/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INDP
• CIK: 1857044
• Web: intecpharma.com
• Phone: (646) 427-2727
• Fax: 972-2586-9176
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +1,708.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -177.27%
• Return on Assets: -141.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.42
• Quick Ratio: 3.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.44 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 16,034,000
• Free Float: 9,957,000
• Market Cap: $7.54 million
• Optionable: Not Optionable
• Beta: 1.62